MeSH D002761 - cholangitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Apotex | Obeticholic acid | Obeticholic Acid | 2023-05-30 | |||
| Intercept Pharmaceuticals | Obeticholic acid | Ocaliva | 2022-02-21 | 2016-05-27 | $8.8 M | Q3/16-Q3/17 |
| Lupin Research | Obeticholic acid | Obeticholic Acid | 2023-05-30 | |||
| MSN Laboratories | Obeticholic acid | Obeticholic Acid | 2023-05-30 | |||
| ADVANZ PHARMA | Obeticholic acid | Ocaliva | 2016-12-12 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
20%2/10
Phase 3
100%1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use